Zobrazeno 1 - 10
of 67
pro vyhledávání: ''
Autor:
Murakami, Rimi1 rimimurakami@gmail.com, Chen, Chiehfeng clifchen@tmu.edu.tw, Lyu, Shu-Yu sylyu@tmu.edu.tw, Lin, Ching-En1 b9102102@stmail.cgu.edu.tw, Tzeng, Pei-Chuan2 peich1981@gmail.com, Wang, Tzu-Feng1 mercyw@gmail.com, Chang, Juei-Chin1 jueichin@hotmail.com, Shieh, Ying-Hua1 syh001@tmu.edu.tw, Chen, I.-Fan3 yvonne@fusenrubber.com, Huang, Shihping4 ksph@nctu.edu.tw, Lin, Hui-Wen d102090015@tmu.edu.tw
Publikováno v:
SpringerPlus. 11/8/2016, Vol. 5 Issue 1, p1-10. 10p.
Autor:
Friederike Hans, Kirsten Hattermann, Rolf Mentlein, Ralph Lucius, Janka Held-Feindt, Eric Holzenburg
Publikováno v:
Cell and Tissue Research
The chemokine CXCL12 (stromal cell-derived factor-1, SDF-1) and its receptor CXCR4 play a major role in tumor initiation, promotion, progression and metastasis, especially for breast cancer cells. Recently, CXCR7 has been identified as a second recep
Autor:
Feng Jin, Fan Yao, Yanan Sun, Ayao Guo, Chong Liu, Quanxiu Jin, Chuifeng Fan, Xiaoyun Mao, Bo Li, Shu Guan
Publikováno v:
Tumour Biology
CXCR4 and its ligand CXCL12 can promote the proliferation, survival, and invasion of cancer cells. They have been shown to play an important role in regulating metastasis of breast cancer to specific organs. High CXCR4 expression was also correlated
Autor:
Annele Sainio, Mikko Savontaus, Hannu Järveläinen, Tanja Kakko, Mirva Söderström, Pia Boström
Publikováno v:
Histochemistry and Cell Biology
The small extracellular matrix proteoglycan decorin which possesses a potent antitumor activity has been shown to be present in various amounts in the stroma of several tumors including those of the breast. Regarding decorin in breast malignancies th
Publikováno v:
European Journal of Nutrition
Purpose Tamoxifen has been used for the treatment of estrogen receptor (ER)-positive breast cancers and in women who are at an increased risk of breast cancer. Acquired resistance to this drug and its toxicity still pose a clinically significant prob
Autor:
Zhu Liu, Jie Ran, Jun Zhou, Min Liu, Bing Yan, Youguang Luo, Dengwen Li, Xin Dong, Jie Chen, Ruming Liu
Publikováno v:
Protein & Cell
Paclitaxel is a microtubule-targeting agent widely used for the treatment of many solid tumors. However, patients show variable sensitivity to this drug, and effective diagnostic tests predicting drug sensitivity remain to be investigated. Herein, we
Autor:
Gwyn T. Williams, Carlos Caldas, Mirna Mourtada-Maarabouni, Andrew R. Green, Mark R. Pickard, Ian O. Ellis, Vanessa L. Hedge
Publikováno v:
Breast Cancer Research : BCR
INTRODUCTION: Programmed cell death through apoptosis plays an essential role in the hormone-regulated physiological turnover of mammary tissue. Failure of this active gene-dependent process is central both to the development of breast cancer and to
Publikováno v:
BMC Cancer
BMC Cancer, Vol 8, Iss 1, p 153 (2008)
BMC Cancer, Vol 8, Iss 1, p 153 (2008)
Background A number of protein markers have been investigated as prognostic adjuncts in breast cancer but their translation into clinical practice has been impeded by a lack of appropriate validation. Recently, we showed that BCL2 protein expression
Publikováno v:
Breast Cancer Research : BCR
Introduction Proteasome inhibition provides an attractive approach to cancer therapy and may have application in the treatment of breast cancer. However, results of recent clinical trials to evaluate the effect of the proteasome inhibitor Bortezomib
Publikováno v:
BMC Cancer
Background Although mammary microcalcification is frequently observed and has been associated with poor survival in patients with breast cancer, the genesis of calcification remains unclear. Carbonic anhydrase I (CA1) has been shown to promote calcif